Trending Stock News

American Century Companies Has Cut Fiserv (FISV) Stake By $22.66 Million; Bb Biotech Ag Has Lowered By $7.62 Million Its Alnylam Pharmaceuticals (ALNY) Stake

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Bb Biotech Ag decreased Alnylam Pharmaceuticals Inc. (ALNY) stake by 5.4% reported in 2017Q4 SEC filing. Bb Biotech Ag sold 60,000 shares as Alnylam Pharmaceuticals Inc. (ALNY)’s stock rose 5.82%. The Bb Biotech Ag holds 1.05M shares with $133.57M value, down from 1.11 million last quarter. Alnylam Pharmaceuticals Inc. now has $10.16B valuation. The stock decreased 1.73% or $1.78 during the last trading session, reaching $101.03. About 353,942 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since May 21, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

American Century Companies Inc decreased Fiserv Inc (FISV) stake by 18.16% reported in 2017Q4 SEC filing. American Century Companies Inc sold 172,972 shares as Fiserv Inc (FISV)’s stock rose 7.86%. The American Century Companies Inc holds 779,306 shares with $102.19M value, down from 952,278 last quarter. Fiserv Inc now has $30.06B valuation. The stock increased 0.59% or $0.43 during the last trading session, reaching $73.41. About 574,682 shares traded. Fiserv, Inc. (NASDAQ:FISV) has risen 21.71% since May 21, 2017 and is uptrending. It has outperformed by 10.16% the S&P500.

Among 24 analysts covering Fiserv (NASDAQ:FISV), 10 have Buy rating, 1 Sell and 13 Hold. Therefore 42% are positive. Fiserv had 61 analyst reports since July 30, 2015 according to SRatingsIntel. JP Morgan maintained it with “Neutral” rating and $95 target in Friday, August 14 report. Monness Crespi maintained the stock with “Buy” rating in Monday, January 9 report. Sterne Agee CRT initiated the shares of FISV in report on Thursday, December 17 with “Buy” rating. Stephens maintained Fiserv, Inc. (NASDAQ:FISV) rating on Monday, February 5. Stephens has “Hold” rating and $145.0 target. RBC Capital Markets maintained Fiserv, Inc. (NASDAQ:FISV) on Tuesday, September 5 with “Hold” rating. The stock of Fiserv, Inc. (NASDAQ:FISV) has “Hold” rating given on Monday, July 10 by Cowen & Co. The stock of Fiserv, Inc. (NASDAQ:FISV) earned “Buy” rating by Guggenheim on Monday, July 17. On Wednesday, May 2 the stock rating was maintained by Credit Suisse with “Neutral”. Barclays Capital maintained Fiserv, Inc. (NASDAQ:FISV) rating on Wednesday, August 2. Barclays Capital has “Equal-Weight” rating and $123 target. The firm earned “Hold” rating on Friday, October 7 by Cantor Fitzgerald.

Investors sentiment increased to 0.81 in Q4 2017. Its up 0.08, from 0.73 in 2017Q3. It increased, as 25 investors sold FISV shares while 292 reduced holdings. 81 funds opened positions while 176 raised stakes. 177.89 million shares or 1.23% less from 180.11 million shares in 2017Q3 were reported. Nuveen Asset Mgmt Llc invested 0% in Fiserv, Inc. (NASDAQ:FISV). Blackrock holds 15.05M shares or 0.09% of its portfolio. Martin Currie, United Kingdom-based fund reported 32,151 shares. Baystate Wealth Ltd Liability Co stated it has 0.03% in Fiserv, Inc. (NASDAQ:FISV). Jarislowsky Fraser Ltd invested in 0.69% or 907,729 shares. Charter has invested 0.03% in Fiserv, Inc. (NASDAQ:FISV). Ngam Advisors Limited Partnership reported 0.09% of its portfolio in Fiserv, Inc. (NASDAQ:FISV). Front Barnett Assoc Limited Liability Corp reported 9,874 shares. Associated Banc reported 0.01% of its portfolio in Fiserv, Inc. (NASDAQ:FISV). The Georgia-based Smith & Howard Wealth Lc has invested 4.98% in Fiserv, Inc. (NASDAQ:FISV). First Republic Invest Mngmt reported 24,726 shares stake. Evercore Wealth Management Ltd has invested 0% in Fiserv, Inc. (NASDAQ:FISV). Rampart Mngmt Company Lc reported 2,842 shares. Balyasny Asset Mngmt Limited Liability Co owns 18,905 shares for 0.01% of their portfolio. Lenox Wealth Mngmt Inc has 40 shares.

American Century Companies Inc increased Evertec Inc (NYSE:EVTC) stake by 563,490 shares to 2.65M valued at $36.10 million in 2017Q4. It also upped Catalent Inc (NYSE:CTLT) stake by 2.32 million shares and now owns 2.63 million shares. Laredo Petroleum Inc (NYSE:LPI) was raised too.

Since December 11, 2017, it had 1 buy, and 6 sales for $11.91 million activity. Shares for $49,981 were bought by DiSimone Harry on Wednesday, February 21. $1.31M worth of stock was sold by VIELEHR BYRON C on Friday, December 15. OLEARY DENIS sold $1.73M worth of stock. YABUKI JEFFERY W also sold $2.36M worth of Fiserv, Inc. (NASDAQ:FISV) shares. 3,439 shares were sold by Schultz Kevin J, worth $452,263 on Monday, December 11.

Analysts await Fiserv, Inc. (NASDAQ:FISV) to report earnings on August, 7. They expect $0.74 earnings per share, up 23.33% or $0.14 from last year’s $0.6 per share. FISV’s profit will be $302.99M for 24.80 P/E if the $0.74 EPS becomes a reality. After $0.76 actual earnings per share reported by Fiserv, Inc. for the previous quarter, Wall Street now forecasts -2.63% negative EPS growth.

Since January 4, 2018, it had 0 insider buys, and 10 insider sales for $38.04 million activity. On Thursday, January 4 the insider Mason Michael sold $4.84M. The insider Vaishnaw Akshay sold $12.67 million. The insider SHARP PHILIP A sold $1.94 million. $4.17M worth of stock was sold by SCHIMMEL PAUL on Tuesday, March 13. Greenstreet Yvonne also sold $985,958 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares. $5.50 million worth of stock was sold by Greene Barry E on Wednesday, March 14. The insider Ausiello Dennis A sold $2.57M.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 earnings per share, down 27.61% or $0.37 from last year’s $-1.34 per share. After $-1.41 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28% negative EPS growth.

Investors sentiment increased to 2.03 in Q4 2017. Its up 1.11, from 0.92 in 2017Q3. It is positive, as 27 investors sold ALNY shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) owns 19,674 shares for 0.02% of their portfolio. Jp Marvel Inv Advsr Llc accumulated 2,000 shares. Moreover, Barclays Plc has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). British Columbia Invest Mngmt invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Weiss Asset Mgmt Ltd Partnership, a Massachusetts-based fund reported 2,460 shares. 17,321 are owned by Employees Retirement Association Of Colorado. Tarbox Family Office, a California-based fund reported 20 shares. Voloridge Invest Mngmt Ltd Co reported 13,013 shares stake. Aqr Cap Management Ltd Liability Co holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 6,545 shares. Stratos Wealth Prtn Ltd holds 200 shares or 0% of its portfolio. Geode Cap Management Limited Co holds 0.03% or 747,646 shares in its portfolio. Suntrust Banks Inc holds 9,944 shares or 0.01% of its portfolio. Hemenway Trust Ltd Company invested in 0.05% or 2,183 shares. Rhumbline Advisers reported 0.03% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). M&T Financial Bank Corp reported 0% stake.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals: Hitting The Next Growth Curve” on April 25, 2018, also Fool.com with their article: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” published on May 17, 2018, Seekingalpha.com published: “Alnylam Pharmaceuticals (ALNY) Q1 2018 Results – Earnings Call Transcript” on May 04, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Nasdaq.com and their article: “Ionis Pharmaceuticals Prepares for Launch” published on May 09, 2018 as well as Fool.com‘s news article titled: “Alnylam Looks Forward” with publication date: May 08, 2018.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 107 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, August 28 the stock rating was maintained by JMP Securities with “Outperform”. The firm earned “Buy” rating on Thursday, September 21 by Barclays Capital. Piper Jaffray maintained it with “Buy” rating and $182.0 target in Friday, December 15 report. Piper Jaffray maintained the shares of ALNY in report on Friday, November 17 with “Buy” rating. The firm earned “Overweight” rating on Monday, August 31 by Piper Jaffray. The firm has “Buy” rating by Ladenburg Thalmann given on Thursday, February 2. The firm earned “Buy” rating on Thursday, October 6 by Chardan Capital Markets. Needham maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, October 6. Needham has “Buy” rating and $137 target. The rating was maintained by Jefferies on Friday, August 5 with “Buy”. Chardan Capital Markets maintained the stock with “Buy” rating in Wednesday, November 30 report.

Fiserv, Inc. (NASDAQ:FISV) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *